IDARUBICIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Idarubicin Hydrochloride patents expire, and what generic alternatives are available?
Idarubicin Hydrochloride is a drug marketed by Fresenius Kabi Usa, Hikma, Meitheal, Rising, Sandoz, and Teva Parenteral. and is included in seven NDAs.
The generic ingredient in IDARUBICIN HYDROCHLORIDE is idarubicin hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the idarubicin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Idarubicin Hydrochloride
A generic version of IDARUBICIN HYDROCHLORIDE was approved as idarubicin hydrochloride by MEITHEAL on May 1st, 2002.
Summary for IDARUBICIN HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 7 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 66 |
Clinical Trials: | 270 |
Patent Applications: | 6,273 |
Formulation / Manufacturing: | see details |
DailyMed Link: | IDARUBICIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for IDARUBICIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ho Joon Im | Phase 2 |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 |
Zhongda Hospital | Phase 2/Phase 3 |
Pharmacology for IDARUBICIN HYDROCHLORIDE
Drug Class | Anthracycline Topoisomerase Inhibitor |
Mechanism of Action | Topoisomerase Inhibitors |